GSK Sees Light At End Of Shingrix Tunnel As COVID-19 Eases

Company Records Steep Sales Decline For Shingles Vaccine in Q1

 
• By Alaric DeArment
Shingles_1200
GSK forecasts stronger sales for its shingles vaccine, Shingrix, in the latter half of 2021 and 2022 • Source: Shutterstock

More from Earnings

More from Business